bm|t logo

NEWS

March, 1 2021 InflaRx, a bm|t Investee-Partner, completed a minimum 75 Mio. USD equity raise, greatly enhancing the company’s ability to continue advancing its promising pipeline through multiple significant milestones.

InflaRx N.V. (Nas­daq: IFRX), a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany devel­op­ing anti-inflam­ma­tory ther­a­peu­tics by tar­get­ing the com­ple­ment sys­tem, announced today that it has com­pleted its under­writ­ten pub­lic offer­ing of 15,000,000 com­mon shares at a price of $5.00 per share. For each com­mon share pur­chased, an investor received a war­rant to pur­chase a com­mon share at an exer­cise price of $5.80. The gross pro­ceeds to InflaRx from the offer­ing were approx­i­mately $75 mil­lion, before deduct­ing the under­writ­ing dis­count and other offer­ing expenses and exclud­ing the exer­cise of any war­rants. The Com­pany intends to use the net pro­ceeds from the offer­ing pri­mar­ily to fund research and devel­op­ment expenses for its clin­i­cal and pre­clin­i­cal research and devel­op­ment activ­i­ties and for work­ing cap­i­tal and gen­eral cor­po­rate purposes.Guggenheim Secu­ri­ties, LLC and Ray­mond James & Asso­ciates, Inc. served as joint book-run­ning man­agers for the offering.A shelf reg­is­tra­tion state­ment relat­ing to the secu­ri­ties being sold in this offer­ing was filed with the U.S. Secu­ri­ties and Exchange Com­mis­sion (the “SEC”) and was declared effec­tive by the SEC on July 17, 2020. The offer­ing was made only by means of a prospec­tus and a prospec­tus sup­ple­ment. A prospec­tus sup­ple­ment and accom­pa­ny­ing prospec­tus related to the offer­ing have been filed with the SEC and are avail­able at the SEC’s web­site located at www.sec.gov. Copies of the prospec­tus sup­ple­ment and accom­pa­ny­ing prospec­tus related to the offer­ing may be obtained by con­tact­ing Guggen­heim Secu­ri­ties, LLC, Atten­tion: Equity Syn­di­cate Depart­ment, 330 Madi­son, 8th Floor, New York, NY 10017, or by tele­phone at (212) 518‑9544, or by email to GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not con­sti­tute an offer to sell or a solic­i­ta­tion of an offer to buy these secu­ri­ties, nor shall there be any sale of these secu­ri­ties in any state or juris­dic­tion in which such offer, solic­i­ta­tion or sale would be unlaw­ful prior to reg­is­tra­tion or qual­i­fi­ca­tion under the secu­ri­ties laws of any such state or jurisdiction.

About InflaRx N.V.:
InflaRx (Nas­daq: IFRX) is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany focused on apply­ing its pro­pri­etary anti-C5a tech­nol­ogy to dis­cover and develop first-in-class, potent and spe­cific inhibitors of C5a. Com­ple­ment C5a is a pow­er­ful inflam­ma­tory medi­a­tor involved in the pro­gres­sion of a wide vari­ety of autoim­mune and other inflam­ma­tory dis­eases. InflaRx was founded in 2007, and the group has offices and sub­sidiaries in Jena and Munich, Ger­many, as well as Ann Arbor, MI, USA.
Contacts:

InflaRx N.V.

Jor­dan Zwick – Chief Strat­egy Officer
Email:jordan.zwick[at]inflarx.de
Tel: +1 917−338−6523

MC Ser­vices AG

Katja Arnold, Lau­rie Doyle, Andreas Jungfer
Email:inflarx[at]mc-services.eu
Europe: +49 89–210 2280
US: +1–339-832‑0752

 

FORWARD-LOOKING STATEMENTS
This press release con­tains for­ward-look­ing state­ments. All state­ments other than state­ments of his­tor­i­cal fact are for­ward-look­ing state­ments, which are often indi­cated by terms such as “may,” “will,” “should,” “expect,” “plan,” “antic­i­pate,” “could,” “intend,” “tar­get,” “project,” “believe,” “esti­mate,” “pre­dict,” “poten­tial” or “con­tinue” and sim­i­lar expres­sions. For­ward-look­ing state­ments appear in a num­ber of places through­out this release and may include state­ments regard­ing our inten­tions, beliefs, pro­jec­tions, out­look, analy­ses and cur­rent expec­ta­tions con­cern­ing, among other things, our ongo­ing and planned pre­clin­i­cal devel­op­ment and clin­i­cal tri­als; the impact of the COVID-19 pan­demic on the Com­pany; the tim­ing and our abil­ity to com­mence and con­duct clin­i­cal tri­als; poten­tial results from cur­rent or poten­tial future col­lab­o­ra­tions; our abil­ity to make reg­u­la­tory fil­ings, obtain pos­i­tive guid­ance from reg­u­la­tors, and obtain and main­tain reg­u­la­tory approvals for our prod­uct can­di­dates; our intel­lec­tual prop­erty posi­tion; our abil­ity to develop com­mer­cial func­tions; expec­ta­tions regard­ing clin­i­cal trial data; our results of oper­a­tions, cash needs, finan­cial con­di­tion, liq­uid­ity, prospects, future trans­ac­tions, growth and strate­gies; the indus­try in which we oper­ate; the trends that may affect the indus­try or us and the risks uncer­tain­ties and other fac­tors described under the head­ing “Risk Fac­tors” in InflaRx’s peri­odic fil­ings with the Secu­ri­ties and Exchange Com­mis­sion. These state­ments speak only as of the date of this press release and involve known and unknown risks, uncer­tain­ties and other impor­tant fac­tors that may cause our actual results, per­for­mance or achieve­ments to be mate­ri­ally dif­fer­ent from any future results, per­for­mance or achieve­ments expressed or implied by the for­ward-look­ing state­ments. Given these risks, uncer­tain­ties and other fac­tors, you should not place undue reliance on these for­ward-look­ing state­ments, and we assume no oblig­a­tion to update these for­ward-look­ing state­ments, even if new infor­ma­tion becomes avail­able in the future, except as required by law.
news overview
Archiv